in 2020, under control of private equity group PAI Partners) for USD 138 million 2011 October: acquired American firm Arch Chemicals for $1.4 billion, thus becoming the world's largest manufacturer of biocides. 2016 August 15: announced $300mio acquisition of US based InterHealth Nutraceuticals, a leader in research, development, manufacture and marketing of value-added nutritional ingredients for use in dietary supplements. 2016 December : announced acquisition of Capsugel for from private equity firm KKR. 2017 February, announced construction of a CHF 290 million biopharmaceuticals plant (with the French pharmaceutical company Sanofi) in Visp. 2021 July, Lonza Specialty Ingredients divested to Bain and Cinven for CHF 4.2 billion. Lonza is involved in the manufacturing of biologics with several pharmaceutical companies. Lonza entered into a partnership with Teva in 2009 to develop and manufacture biosimilars. In 2010, they made a deal with GlaxoSmithKline to manufacture therapeutic monoclonal antibodies. In 2014, Lonza entered into an agreement with Bristol-Myers Squibb to manufacture two biologic drugs. Lonza also manufactures Imbruvica for Pharmacyclics and Mydicar for Celladon. In 2015, Lonza contracted with Alexion to construct a new facility dedicated to Alexion manufacturing. In 2017, Lonza and Sanofi partnered to construct a new facility for production of biologics. In May 2020, Moderna struck a manufacturing deal with Lonza to produce its (mRNA-1273) COVID-19 vaccine active ingredient while expanding sterile production and fill-finish activities to 500 million doses starting in 2021. Production of the mRNA bulk vaccine started in January 2021, soon after an official visit by Swiss Federal Councilor Alain Berset. Lonza Group is responsible for the global production of two-thirds of the raw materials for the Moderna vaccine at combined U.S. and Swiss facilities. The company also started to collaborate with Altimmune Inc. for the development of a nasal COVID-19 vaccine. Corporate structure As of 2020, Lonza's business areas include: Small Molecules: active pharmaceutical ingredients, drug product formulation Biologics: mammalian, microbial, licensing, bioconjugates, parenteral drug product services, mRNA Cell & Gene: cell and gene technologies, personalized medicine, bioscience Capsules & Health Ingredients: capsules, health ingredients In November 2019, Chairman Albert Baehny became both chairman and interim CEO of Lonza after chief executive officer (CEO) Marc Funk left after 9 months. In November 2020, Pierre-Alain Ruffieux commenced his role as Chief Executive Officer. Business operations , Lonza had twenty-four self-described major sites located in the United States, India, the Czech Republic, Belgium, Spain, China, France, South Africa, Switzerland,